메뉴 건너뛰기




Volumn 87, Issue 9, 2016, Pages 944-951

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

(32)  Patti, F a   Messina, S a   Solaro, C b   Amato, M P c   Bergamaschi, R d   Bonavita, S e   Bruno Bossio, R f   Brescia Morra, V e   Costantino, G F g   Cavalla, P h   Centonze, D i,j   Comi, G k   Cottone, S l   Danni, M m   Francia, A n   Gajofatto, A o   Gasperini, C p   Ghezzi, A q   Iudice, A r   Lus, G s   more..


Author keywords

[No Author keywords available]

Indexed keywords

NABIXIMOLS;

EID: 84969138568     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-312591     Document Type: Article
Times cited : (82)

References (21)
  • 1
    • 79953881245 scopus 로고    scopus 로고
    • Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: The '5E' study
    • Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev Pharmacoecon Outcomes Res 2011;11:205-13.
    • (2011) Expert Rev Pharmacoecon Outcomes Res , vol.11 , pp. 205-213
    • Arroyo, R.1    Vila, C.2    Clissold, S.3
  • 2
    • 4444288689 scopus 로고    scopus 로고
    • Prevalence and treatment of spasticity reported by multiple sclerosis patients
    • Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-95.
    • (2004) Mult Scler , vol.10 , pp. 589-595
    • Rizzo, M.A.1    Hadjimichael, O.C.2    Preiningerova, J.3
  • 3
    • 84893487075 scopus 로고    scopus 로고
    • Overview of MS spasticity
    • Pozzilli C. Overview of MS spasticity. Eur Neurol 2014;71(Suppl 1):1-3.
    • (2014) Eur Neurol , vol.71 , pp. 1-3
    • Pozzilli, C.1
  • 4
    • 0346733218 scopus 로고    scopus 로고
    • Treatments for spasticity and pain in multiple sclerosis: A systematic review
    • iii ix-x
    • Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:iii, ix-x, 1-111.
    • (2003) Health Technol Assess , vol.7 , pp. 1-111
    • Beard, S.1    Hunn, A.2    Wight, J.3
  • 6
    • 33847766180 scopus 로고    scopus 로고
    • Sativex spasticity in MSSG. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
    • Collin C, Davies P, Mutiboko IK, et al, Sativex spasticity in MSSG. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
    • (2007) Eur J Neurol , vol.14 , pp. 290-296
    • Collin, C.1    Davies, P.2    Mutiboko, I.K.3
  • 7
    • 84937953069 scopus 로고    scopus 로고
    • Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis
    • Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 2015;15:909-18.
    • (2015) Expert Rev Neurother , vol.15 , pp. 909-918
    • Meuth, S.G.1    Vila, C.2    Dechant, K.L.3
  • 8
    • 33749427038 scopus 로고    scopus 로고
    • Combined cannabinoid therapy via an oromucosal spray
    • Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42:495-503.
    • (2006) Drugs Today (Barc , vol.42 , pp. 495-503
    • Perez, J.1
  • 9
    • 4344582253 scopus 로고    scopus 로고
    • Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
    • Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
    • (2004) Mult Scler , vol.10 , pp. 434-441
    • Wade, D.T.1    Makela, P.2    Robson, P.3
  • 10
    • 33745025055 scopus 로고    scopus 로고
    • Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
    • Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45.
    • (2006) Mult Scler , vol.12 , pp. 639-645
    • Wade, D.T.1    Makela, P.M.2    House, H.3
  • 11
    • 77952835462 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    • Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9.
    • (2010) Neurol Res , vol.32 , pp. 451-459
    • Collin, C.1    Ehler, E.2    Waberzinek, G.3
  • 12
    • 79953822342 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
    • Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31.
    • (2011) Eur J Neurol , vol.18 , pp. 1122-1131
    • Novotna, A.1    Mares, J.2    Ratcliffe, S.3
  • 13
    • 84910039391 scopus 로고    scopus 로고
    • Advances in the management of MS spasticity: Recent observational studies
    • Fernández O. Advances in the management of MS spasticity: recent observational studies. Eur Neurol 2014;72(Suppl 1):12-14.
    • (2014) Eur Neurol , vol.72 , pp. 12-14
    • Fernández, O.1
  • 14
    • 84977776225 scopus 로고    scopus 로고
    • An observational post-approval registry study of patients prescribed Sativex ®. Results from clinical practice. [Poster 1041]
    • Eltayb A, Etges T, Wright S. An observational post-approval registry study of patients prescribed Sativex ®. Results from clinical practice. [Poster 1041]. Mult Scler 2013;19(Suppl 1):74.
    • (2013) Mult Scler , vol.19 , pp. 74
    • Eltayb, A.1    Etges, T.2    Wright, S.3
  • 15
    • 84900428298 scopus 로고    scopus 로고
    • Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity
    • Koehler J, Feneberg W, Meier M, et al. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 2014;124:652-6.
    • (2014) Int J Neurosci , vol.124 , pp. 652-656
    • Koehler, J.1    Feneberg, W.2    Meier, M.3
  • 16
    • 84901684390 scopus 로고    scopus 로고
    • Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity
    • Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71:271-9.
    • (2014) Eur Neurol , vol.71 , pp. 271-279
    • Flachenecker, P.1    Henze, T.2    Zettl, U.K.3
  • 17
    • 84995703921 scopus 로고    scopus 로고
    • Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity
    • Celia Oreja-Guevara BC, Manuel Ordás C, Vila C, et al. Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 2015;5:184.
    • (2015) Clin Exp Pharmacol , vol.5 , pp. 184
    • Celia Oreja-Guevara, B.C.1    Manuel Ordás, C.2    Vila, C.3
  • 18
    • 44849131341 scopus 로고    scopus 로고
    • Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
    • Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-85.
    • (2008) Clin Ther , vol.30 , pp. 974-985
    • Farrar, J.T.1    Troxel, A.B.2    Stott, C.3
  • 19
    • 84902301875 scopus 로고    scopus 로고
    • Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice
    • Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72:95-102.
    • (2014) Eur Neurol , vol.72 , pp. 95-102
    • Flachenecker, P.1    Henze, T.2    Zettl, U.K.3
  • 20
    • 84957838189 scopus 로고    scopus 로고
    • Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study
    • Ferrè L, Nuara A, Pavan G, et al. Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci 2016;37:235-42.
    • (2016) Neurol Sci , vol.37 , pp. 235-242
    • Ferrè, L.1    Nuara, A.2    Pavan, G.3
  • 21
    • 84956795053 scopus 로고    scopus 로고
    • Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis
    • Leocani L, Nuara A, Houdayer E, et al. Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 2015;262: 2520-7.
    • (2015) J Neurol , vol.262 , pp. 2520-2527
    • Leocani, L.1    Nuara, A.2    Houdayer, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.